Why Coherent's Rally May Continue Higher

Coherent Corp. reported Q3 FY2026 revenue of $1.81B, up 21% year over year, with EPS surging 55% and margins expanding to 39.6%. Management expects FY2027 growth to exceed FY2026, even as consensus already points to revenue rising from $7.05B to $9.45B. The company also plans a 4x indium phosphide capacity expansion through 2027, which should improve optical supply availability and production economics.

Analysis

COHR’s setup is not just a demand story; it is a supply-chain re-rating. A 4x indium phosphide buildout implies management sees a multi-year capacity bottleneck that can be monetized before competitors can materially respond, which should widen the gap between the best-capitalized optical suppliers and the rest of the component stack. The second-order effect is better lead times and lower unit costs, which can force smaller peers to compete on price or cede socket share in datacenter and telecom ramps.

The market is likely underappreciating how quickly incremental capacity can convert into mix improvement rather than just volume. If the added output is routed toward higher-margin optical modules, laser components, and specialized materials, COHR can sustain margin expansion even if top-line growth normalizes from current elevated rates. That makes the bull case less dependent on heroic end-demand assumptions and more on operating leverage plus manufacturing throughput.

The main risk is not demand collapse in the next quarter, but capex timing and execution over 6-18 months: yield issues, customer qualification delays, or a broader AI infrastructure digestion period could compress the multiple before the new capacity is fully monetized. A second risk is that a visible capacity step-up invites faster competitive investment, eventually turning a scarcity premium into a price-war narrative by late 2026/2027. In the near term, however, the guide-up trajectory can stay intact even if consensus continues to lag by one or two quarters.

The consensus miss is likely the duration of margin durability, not just earnings inflection. Investors may be anchoring on peak-cycle optical demand, but the combination of constrained supply, capex scale, and operating leverage can keep revisions positive longer than expected. That supports owning pullbacks rather than chasing strength, because the real catalyst path is estimate revisions over the next several reporting cycles, not a one-day post-print squeeze.

Key Decisions for Investors

• Go long COHR on any 3-5% post-earnings pullback; target a 6-12 month hold for estimate revision upside, with downside protected if the stock loses the post-print gap and management commentary turns cautious on qualification timing.
• Use a bullish call spread in COHR 3-6 months out to express upside while limiting multiple-compression risk; risk/reward is attractive if the market keeps rerating optical suppliers on capacity scarcity.
• Pair trade: long COHR / short a less-scaled optical peer or supplier with weaker pricing power over the next 2-4 quarters; thesis is that COHR’s capacity expansion converts into share gains and better cost absorption while smaller names face margin pressure.
• If already long, sell covered calls against COHR into strength after revisions accelerate; the stock can keep grinding higher, but implied vol is likely elevated and better monetized via premium harvest than outright beta exposure.